BioCentury | Oct 28, 2020
Distillery Therapeutics

Targeting the NMDA receptor-TRPM4 complex for neurodegeneration

...Stroke; neurologyDisruption of the NMDA receptor-TRPM4 complex could treat ischemic stroke and other neurodegenerative diseases with NMDA receptor...
...PD studies.TARGET/MARKER/PATHWAY: NMDA receptor; transient receptor potential cation channel subfamily M member 4 (TRPM4); NMDA receptor NR2A subtype (GRIN2A; NR2A); NMDA receptor...
...Science; published online Oct. 9, 2020doi:10.1126/science.aay3302CONTACT: Hilmar Bading, Heidelberg University, Heidelberg, Germanyemail: bading@nbio.uni-heidelberg.de Claire Quang Heidelberg University NMDA receptor NMDA receptor NR2A subtype (GRIN2A) (NR2A) NMDA receptor...
BioCentury | Oct 21, 2020
Finance

Oct. 20 Quick Takes: AbSci raises $65M; plus Aptinyx, Synspira and Aridis

...to $4.47 on Tuesday, touching a 52-week high intraday. The company said late Monday that NMDA receptor...
BioCentury | Sep 30, 2020
Product Development

Ovid looks to broad path forward for rare epilepsy program

Three years after striking a deal with Takeda to take the lead on developing the Japanese pharma’s soticlestat, Ovid is considering multiple paths to market for the therapy in rare epileptic encephalopathies.  On Wednesday, Ovid...
BioCentury | Sep 25, 2020
Emerging Company Profile

XWPharma: timing therapy to biological rhythm

...Johnson Innovation – JJDC WI Harper Group WuXi AppTec KTB Network NMDA receptor GABA...
BioCentury | Apr 30, 2020
Distillery Therapeutics

Inhibiting an NMDA receptor to reduce lupus neurological symptoms

...DISEASE CATEGORY: Autoimmune disease INDICATION: Lupus Antagonists of the NMDA receptor GRIN2A could treat systemic lupus erythematosus...
...dendritic complexity and loss of pyramidal neuron, reduced microglia activation and improved spatial memory. TARGET/MARKER/PATHWAY: NMDA receptor...
...for Medical Research, Northwell Health, Manhasset, N.Y. email: bdiamond@northwell.edu Claire Quang Stony Brook University Feinstein Institute for Medical Research NMDA receptor...
BioCentury | Apr 27, 2020
Product Development

After hitting primary endpoint, Axsome planning second trial in Alzheimer’s agitation

...Already headed for an FDA submission this year in depression, Axsome’s multimodal NMDA receptor agonist now has...
...after a December 2018 futility analysis. AXS-05’s modulated delivery tablets combine dextromethorphan, which is an NMDA receptor...
BioCentury | Mar 20, 2020
Product Development

Axsome speeds Alzheimer's agitation trial, citing patient vulnerability and FDA guidance

...winding down subjects' participation in the 435-patient Phase II/III ADVANCE-1 trial of AXS-05, its multimodal NMDA receptor...
...endpoint measures Cohen-Mansfield Agitation Inventory (CMAI). AXS-05's modulated delivery tablets combine dextromethorphan, which is an NMDA receptor...
BioCentury | Mar 7, 2020
Product Development

If NoNO’s stroke trial strategy pays off, it could bring the first new therapy in a generation

...toxic NMDA receptor signaling in stroke NoNO Inc. is decoupling the signaling pathways downstream of the NMDA receptor...
...NMDA receptor is thought to be one of the primary mechanisms of cell death following stroke. NMDA receptor...
...interaction of the NMDA receptor with the neurotransmitter glutamate, they disrupted all signaling downstream of the NMDA receptor...
BioCentury | Jan 17, 2020
Preclinical News

Jan 16 Preclinical Quick Takes: Deerfield's Orchard partners with Yeda; Acuitas-Penn flu vaccine in newborns; plus Regeneron, Genentech-Gladstone and Banyan

...respectively. The costimulatory bispecifics alone had little activity and no toxicity. Genentech, Gladstone allosterically target NMDA receptor...
...Dravet syndrome and Alzheimer's disease. GNE-0723, a tool compound, is an allosteric enhancer of GRIN2A-containing NMDA receptor...
...“Banyan Reports 97.6% Sensitivity” ). Targets: GFAP - Glial fibrillary acidic protein; GRIN2A (NR2A) - NMDA receptor...
BioCentury | Dec 17, 2019
Clinical News

Axsome continues ascent with Phase III success in depression

...from a Phase II readout of a competing depression candidate also thought to work via NMDA receptor...
...NMDA receptor one thing the three have in common. The GEMINI findings support the idea that NMDA receptor...
...III Trial for Narcolepsy Therapy Following Positive Phase II Data" ). Sandi Wong, Staff Writer AXS-05 Axsome Therapeutics Inc. NMDA receptor major...
Items per page:
1 - 10 of 676